Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Alternative Medicine/Health -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (67)	11/11/1999 11:58:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 357

NBTY? Incredibly fragmented market, with little barrier to entry. I've been trying, for about four years, to find a play that I had confidence in.

To: LLCF who wrote (67)	11/12/1999 8:33:00 PM
From: RWReeves	Respond to of 357

On the subject of Newts (Nutriceuticals)- To get around the fragmentation problem, maybe look at PURW, which is I think the main US manufacturer of the ingredients at the wholesale level has just opened a new plant and added capacity. Selling near the bottom for it's range. Pretty strong balance sheet. Have some of this tucked away. RXSD is one which is interesting for it's distribution channel presence but has been beaten up by price pressure and the troubled cellulite product. It's worth taking a look at as a possible munch for a pharma that wants a ready made distribution chain and some established brand equity. Also snooping around its lows, it briefly soared as a dot-com earlier this year. LOL, a sight to see. Don't have any at the moment, looking for the fire sale. BTW re: a talk we had way back, decent survey article in BW today on immune system memory and reaction to viral challenge, both natural and vaccine based. RWR

To: LLCF who wrote (67)	11/18/1999 5:00:00 PM
From: scaram(o)uche	Respond to of 357

>> Hey, we're on SI... what about some stocks on the subject? << Here's one for you? I know nada........ Thursday November 18, 4:09 pm Eastern Time Company Press Release ENADA NADH Confirmed Aid in Fighting Chronic Fatigue Syndrome CHATSWORTH, Calif.--(BUSINESS WIRE)--Nov. 18, 1999--Natrol Inc. (Nasdaq:NTOL - news), a manufacturer and distributor of nationally branded dietary supplements and a leading distributor of ENADA® NADH (ENADA) manufactured by Menuco Corp., today commented on the release of an FDA-approved study on Chronic Fatigue Syndrome (CFS). CFS is a debilitating disorder that causes unexplainable tiredness or lack of energy. It is estimated that CFS affects more than 14 million Americans. According to a report published by Menuco, ''results of an FDA-approved, double-blind, placebo-controlled cross-over study published in the February 1999 issue of Annals of Allergy, Asthma and Immunology, found that CFS patients taking ENADA, a dietary supplement, were four times more likely to show improvements compared to those taking a placebo. ''A follow-up open label study showed 72 percent of the patients taking ENADA achieved continued marked improvement over time. After more than 18 months of using ENADA more than 80 percent of the CFS patients continue to experience improvement in their condition.'' Natrol is one of the country's largest wholesalers of ENADA to retailers, selling two potencies of ENADA® NADH, 2.5 and 5.0 mg, in 10-count and 30-count blister-packed, under its Natrol brand name. Natrol sells ENADA through multiple channels of distribution, including health foods stores, chain drug stores, food stores, mass market merchants, as well as catalog and Internet retailers. Natrol's President and Chairman, Elliott Balbert, noted when the studies were released: ''that Natrol's mission is to help improve the well being of the average person through the sale of its products. We market ENADA as an energy enhancing, energizing coenzyme because NADH plays a key role in the energy production of our cells and neurotransmitter processes. ''As a supplement company, we have never linked ENADA to CFS. Even so, we can't help but take note of the published study which was conducted by doctors at the Georgetown University Medical Center. Natrol is proud to be associated with Menuco in the distribution of ENADA.'' This release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the company's financial results are beyond the ability of the company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results are described in the company's filings with the Securities and Exchange Commission. Contact: Natrol Inc., Chatsworth Tami Paige, 818/739-6000